Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock

by · The Markets Daily

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) Director Dino Rossi sold 25,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Krystal Biotech Trading Up 1.2%

KRYS traded up $3.93 during midday trading on Friday, hitting $332.27. 167,864 shares of the company traded hands, compared to its average volume of 345,531. The company has a market capitalization of $9.84 billion, a price-to-earnings ratio of 41.64 and a beta of 0.53. Krystal Biotech, Inc. has a 52-week low of $136.73 and a 52-week high of $382.54. The business has a 50 day simple moving average of $343.76 and a two-hundred day simple moving average of $299.02.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The company had revenue of $119.22 million during the quarter, compared to analyst estimates of $120.93 million. Equities research analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Silvant Capital Management LLC acquired a new stake in shares of Krystal Biotech in the 2nd quarter worth $30,000. Western Wealth Management LLC acquired a new position in shares of Krystal Biotech during the 1st quarter valued at about $34,000. Greenline Wealth Management LLC purchased a new stake in shares of Krystal Biotech in the fourth quarter valued at about $34,000. Danske Bank A S purchased a new stake in shares of Krystal Biotech in the third quarter valued at about $35,000. Finally, UMB Bank n.a. increased its position in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock worth $36,000 after purchasing an additional 37 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Analyst Ratings Changes

KRYS has been the topic of several recent research reports. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 5th. HC Wainwright increased their target price on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a research report on Tuesday, June 16th. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a research note on Monday, August 3rd. Jefferies Financial Group restated a “buy” rating and set a $474.00 price target on shares of Krystal Biotech in a research report on Monday, July 13th. Finally, Royal Bank Of Canada assumed coverage on shares of Krystal Biotech in a research note on Friday. They set an “outperform” rating and a $400.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.40.

Check Out Our Latest Report on Krystal Biotech

Krystal Biotech Company Profile

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

Recommended Stories